NCT06417229View on ClinicalTrials.gov

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

February 19, 2025

Study Completion Date

February 19, 2025

Conditions
Healthy Participants
Interventions
DRUG

BMS-986365

Specified dose on specified days

DRUG

Rabeprazole

Specified dose on specified days

Trial Locations (1)

66219

Local Institution - 0001, Lenexa

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT06417229 - Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants | Biotech Hunter | Biotech Hunter